ArticleClinical cardiology2018

Rationale and design of a randomized study to assess the efficacy and safety of evolocumab in patients with diabetes and dyslipidemia: The BERSON clinical trial.

Alberto J Lorenzatti et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.